GATA3-mutant research hub

"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial

This study is testing a new drug, milademetan, alongside an existing treatment, fulvestrant, for a specific type of advanced breast cancer. Researchers want to see if this combination helps shrink tumours or stop their growth in patients with certain genetic markers.